Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1978-5-17
|
| pubmed:abstractText |
Fifty patients with breast cancer refractory to endocrine manipulation and/or combination chemotherapy were treated with mitomycin-C 20 mg/m2 I.V. every 4-6 weeks and megestrol acetate 160 mg daily. Of 48 evaluable patients, 4% achieved complete remission (CR), 23% had partial remission (PR). Median duration of response for CR and PR was 7 months. Non-responders had a median survival of 2 months. The difference in survival of responders (both CR and PR) and non-responders was statistically significant at p less than 0.01 level. Attenuated doses of mitomycin-C were administered at increasing intervals due to cumulative myelosuppressive toxicity.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0008-543X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
41
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
392-5
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:630529-Adult,
pubmed-meshheading:630529-Aged,
pubmed-meshheading:630529-Bone Marrow,
pubmed-meshheading:630529-Breast Neoplasms,
pubmed-meshheading:630529-Drug Resistance,
pubmed-meshheading:630529-Drug Therapy, Combination,
pubmed-meshheading:630529-Female,
pubmed-meshheading:630529-Humans,
pubmed-meshheading:630529-Megestrol,
pubmed-meshheading:630529-Middle Aged,
pubmed-meshheading:630529-Mitomycins,
pubmed-meshheading:630529-Neoplasm Metastasis,
pubmed-meshheading:630529-Remission, Spontaneous,
pubmed-meshheading:630529-Time Factors
|
| pubmed:year |
1978
|
| pubmed:articleTitle |
Mitomycin-C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy.
|
| pubmed:publicationType |
Journal Article
|